Biogen Product revenue, net — Total Revenue increased by 5.1% to $1.75B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.5%, from $1.73B to $1.75B. Over 4 years (FY 2021 to FY 2025), Product revenue, net — Total Revenue shows a downward trend with a -5.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration, strong demand for the product portfolio, or effective pricing strategies, while a decrease may signal loss of market share, patent expirations, or increased competition.
This metric represents the total net sales generated from the company's portfolio of pharmaceutical products after accou...
Comparable to 'Net Product Sales' or 'Total Revenue from Pharmaceutical Products' reported by other large-cap biotechnology and pharmaceutical firms.
biib_segment_product_revenue_net_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.24B | $2.21B | $2.19B | $2.07B | $2.05B | $1.96B | $1.90B | $1.76B | $1.85B | $1.81B | $1.83B | $1.71B | $1.90B | $1.77B | $1.83B | $1.73B | $1.88B | $1.85B | $1.67B | $1.75B |
| QoQ Change | — | -1.4% | -0.6% | -5.8% | -0.6% | -4.5% | -2.9% | -7.4% | +4.7% | -2.2% | +1.5% | -6.6% | +11.0% | -6.9% | +3.6% | -5.8% | +8.8% | -1.7% | -9.7% | +5.1% |
| YoY Change | — | — | — | — | -8.1% | -11.0% | -13.2% | -14.7% | -10.2% | -8.0% | -3.8% | -2.9% | +2.9% | -2.0% | +0.0% | +0.9% | -1.1% | +4.4% | -9.0% | +1.5% |